Figures & data
Figure 1. Attrition of intravitreal anti-VEGF injection claims included for analysis of severe ocular inflammation rates in the US. nAMD, neovascular age-related macular degeneration; IDW, Integrated Data Warehouse; VEGF, vascular endothelial growth factor.Note: Injections were excluded if the administering physician exhibited evidence of “physician instability” (i.e. physicians with abnormally high or low prescribing patterns).
Table 1. Characteristics of patients receiving intravitreal aflibercept and ranibizumab injections for neovascular age-related macular degeneration, US.
Figure 2. Relative risk (RR) of endophthalmitis with aflibercept injections relative to ranibizumab injections in the US; (a) unadjusted, and (b) adjusted results. CI, confidence interval; ER, event rate. Unadjusted results were calculated by Poisson regression. Adjusted results were calculated using the generalized estimating equation model with compound symmetry adjustments; adjustments were made for both injection-level (left/right injection eye, number of prior injections and occurrence of events with prior injections) and patient-level characteristics (age, sex, health plan type and geographical location). *p < 0.05; **p < 0.0001 (χCitation2 test).
Table 2. Crude event rates for severe ocular inflammation claims over time from intravitreal anti-VEGF injections for neovascular age-related macular degeneration, US.